Chronic infection with the hepatitis C virus (HCV) is a relevant cause of anticipated liver-related mortality due to the late onset of complications of cirrhosis, such as hepatocellular carcinoma (HCC) and clinical decompensation [1] [2] [3] [4] [5] . Bleeding from ruptured esophageal varices (EV) or portal hypertensive gastropathy (PHG) is part of clinical decompensation, and comes second to HCC as a cause of death in patients with compensated cirrhosis of any aetiology [6, 7] . As part of the variable natural history of hepatitis C, gastroesophageal varices occur at different rates in patients with cirrhosis, the yearly rate of de novo EV being <10% [8] [9] [10] [11] [12] , with a predicted yearly transition rate from small (F1) to medium/large (F2 or F3) varices between 5% and 30% [12] [13] [14] [15] [16] [17] [18] [19] [20] . A sustained virological response (SVR) to interferon (IFN)-based therapy, which is the standard of care for chronic hepatitis C, was shown to reduce the rates of complications of HCV-related cirrhosis, including bleeding from EV [21] [22] [23] [24] [25] [26] [27] . These studies, however, were not designed in a manner to assess whether IFN therapy could also attenuate development or progression of EV in parallel, and it is still unclear whether a successful IFN therapy can also prevent development of EV. Indeed, in those studies, EV at baseline were not systematically sought in all patients, whereas many patients had received medical or endoscopic treatment of EV prior or during the study period, which in most studies was not long enough to
Chronic infection with the hepatitis C virus (HCV) is a relevant cause of anticipated liver-related mortality due to the late onset of complications of cirrhosis, such as hepatocellular carcinoma (HCC) and clinical decompensation [1] [2] [3] [4] [5] . Bleeding from ruptured esophageal varices (EV) or portal hypertensive gastropathy (PHG) is part of clinical decompensation, and comes second to HCC as a cause of death in patients with compensated cirrhosis of any aetiology [6, 7] . As part of the variable natural history of hepatitis C, gastroesophageal varices occur at different rates in patients with cirrhosis, the yearly rate of de novo EV being <10% [8] [9] [10] [11] [12] , with a predicted yearly transition rate from small (F1) to medium/large (F2 or F3) varices between 5% and 30% [12] [13] [14] [15] [16] [17] [18] [19] [20] . A sustained virological response (SVR) to interferon (IFN)-based therapy, which is the standard of care for chronic hepatitis C, was shown to reduce the rates of complications of HCV-related cirrhosis, including bleeding from EV [21] [22] [23] [24] [25] [26] [27] . These studies, however, were not designed in a manner to assess whether IFN therapy could also attenuate development or progression of EV in parallel, and it is still unclear whether a successful IFN therapy can also prevent development of EV. Indeed, in those studies, EV at baseline were not systematically sought in all patients, whereas many patients had received medical or endoscopic treatment of EV prior or during the study period, which in most studies was not long enough to
Original article
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ ribavirin therapy Roberta 
Introduction
capture bleeding episodes that occur in the late stage of the disease and only in a minority of patients with HCV cirrhosis [6] . Recently, a subanalysis of a large scale prospective study aimed at evaluating the longterm outcome of patients with compensated HCV-related cirrhosis reported prevention of de novo EV in 34 patients achieving an SVR to IFN-based therapies [28] , thus adding further support to previous observations of reduced porto-caval pressure gradient in patients with HCV cirrhosis who achieved an SVR to IFN/ribavirin (RBV) therapy [29, 30] . To assess the effect of IFN/RBV therapy on the natural course of esophageal varices in HCV compensated cirrhotics, in terms of development or progression in size of pre-existing EV, in the year 2000 we designed an open label prospective study in previously untreated patients.
Methods
This was an open label prospective study of previously untreated patients with HCV-related cirrhosis undergoing IFN/RBV therapy. Enrolment started on January 2000 and finished in March 2006; during this period, all previously untreated patients with cirrhosis attending the Liver Clinic at Maggiore Hospital with ≥1 year serum positivity for serum HCV RNA, alanine aminotransferase (ALT) levels >1.5× the upper limit of normal and a liver biopsy, performed in the 2 years preceding treatment and consistent with incomplete (Ishak 5) or complete (Ishak 6) cirrhosis, were evaluated [31] . Patients were enrolled in the study if they had a compensated liver disease (Child-Pugh A), no previous clinical decompensation such as jaundice, ascites, encephalopathy or variceal bleeding, no HCC and the willingness to undergo endoscopic surveillance, independently of the treatment outcome. Patients were excluded if they had coinfection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV), drug dependence or >40 g/day alcohol intake. Patients who in the past received medical or endoscopic treatment for EV, had F2 or F3 varices and/or moderate or severe PHG, were excluded. Poorly controlled diabetes, severe depression, autoimmune diseases or concomitant malignant neoplastic diseases were also exclusion criteria. The protocol was approved by the Institutional Review Board of our Hospital (Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All patients gave their written informed consent to receive both anti-HCV therapy and endoscopic surveillance, as well as the permission for use of their medical records.
Study end points
The end points of the study were the rate of development and/or progression in size/severity of pre-existing EV, and bleeding from EV in patients receiving anti-HCV therapy. Progression in size of EV was the transition from small to medium/large EV according to the Japanese classification [32] .
Interferon/ribavirin therapy
In the year 2000, a 48-week treatment with IFN-α2b (IntronA; Schering-Plough Corp., Kenilworth, NJ, USA) at doses of 3 MU three times weekly associated with 800-1,200 mg/day RBV (Rebetol; ScheringPlough Corp.) was the standard of care for HCV-1-and HCV-4-infected patients. In patients with HCV-2 or HCV-3, treatment duration was 24 weeks. In September 2001 standard IFN was replaced by pegylated (PEG)-IFN-α2b (PegIntron; Schering-Plough Corp.) at doses of 1.5 µg/kg once per week subcutaneously. RBV was dosed according to baseline weight, that is, 800 mg for patients <65 kg, 1,000 mg for 65-85 kg and 1,200 mg for >85 kg. In September 2003, PEG-IFN-α2a (Pegasys; Hoffman-La Roche, Nutley, NJ, USA) became commercially available at a fixed dose of 180 µg weekly coupled with weight-based dosing of RBV in HCV-1 and HCV-4 (1,000 mg/day for <75 kg and 1,200 mg/day for >75 kg) and a fixed dose of RBV of 800 mg/day in HCV-2 and HCV-3 patients.
Measurements
Serum ALT and aspartate aminotransferase (AST) activities were measured by an automated method at 37°C (normal value ≤37 IU/l); routine blood examinations were regularly performed using standard methods. Qualitative serum HCV RNA was assessed by in-house nested RT-PCR, using specific primers from the 5′ noncoding region with a limit sensitivity of approximately 25 IU/ml at baseline and during treatment at weeks 4, 12, 24 and 48, and at weeks 4, 12 and 24 following treatment completion. HCV was genotyped by a nested RT-PCR, using universal biotinylated primers in the 5′ non-coding region (Line Probe Assay, Inno-Lipa HCV 2; Innogenetics, Zwijndrecht, Belgium). Serum HCV-RNA was quantified by Versant HCV RNA 3.0 assay (bDNA 3.0; Bayer Corporation, Emeryville, CA, USA), with a sensitivity limit of 615 IU/ml and a dynamic range from 615-7,700,000 IU/ml. Commercially available enzyme immunoassays were used to determine serum hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis A virus (HAV) and HIV. Antibodies to nuclear, smooth muscle, mitochondrial, and liver and kidney microsomal antigens were assayed on rat liver and kidney cryostat sections by immunofluorescence. Antinuclear antibodies were confirmed on Hep-2 cells. Alcohol abuse was excluded by patients' clinical interviews. The presence of HCC was excluded on the basis of ultrasound evaluation and serum α-fetoprotein measurement at baseline.
Liver biopsies were performed with a 16 gauge Tru-Cut needle (Tru-Cut 16 G; TSK, Tokyo, Japan), and read by a single pathologist (MFD). Liver biopsies were considered to be adequate for fibrosis assessment if they were longer than 15 mm or had ≥12 portal tracts. The severity of hepatic inflammation was evaluated by the Ishak score in separate reports for grading and staging. The maximum score for grading was 18, ranging from 0 to 4 for piecemeal necrosis, focal necrosis, and portal inflammation, and from 0 to 6 for confluent necrosis. The score for staging ranged from 0, no fibrosis, to 6, cirrhosis [31] ; all patients enrolled in this study had a staging ≥5. Disease duration was calculated by considering as the onset of infection the date of blood transfusion received prior to 1992 or the period of drug injection. In patients with unknown source of infection, the date of the first abnormal ALT test was arbitrarily taken as the start of infection.
Definition of response
Serum HCV RNA by in-house nested RT-PCR was assessed at week 12 (early virological response), at week 24, and at week 48 of treatment (end-of-treatment response). HCV-1 and -4 patients who were still HCV RNA-positive at week 12 were tested for quantitative HCV RNA, and kept on treatment if a decrease of ≥2 log in viraemia was observed (partial early virological response); they stopped therapy if HCV RNA was still detectable at week 24. An SVR was undetectable HCV RNA by RT-PCR at week 24 post-treatment. Patients with an end-of-treatment response who tested HCV RNA-positive during follow-up, were classified as relapsers. Patients who had any other virological response, were considered as non-responders.
Upper gastrointestinal endoscopy
All patients underwent esophago-gastroduodenoscopy (EGDS) within 6 months before starting antiviral treatment and after had an EGDS repeated every 2 years by the same endoscopists (RdF, MP and AD), who were blinded to treatment outcome. EV were classified according to the North Italian Endoscopic Club criteria [11] , size and location of EV and the presence of red wale marks (RWM) were assessed at all endoscopies [33] . Bleeding from EV or PHG was defined by the III Baveno International Consensus criteria [16] .
Statistical analysis
Continuous variables were reported as median (range), and categorical variables as frequencies (percentages). Comparisons between groups were performed using the Student's t test or the Mann-Whitney U test for continuous variables, and χ 2 test or the Fisher's exact test for categorical variables. The variables significantly associated with EV development at univariate analysis were entered into a logistic regression analysis. Time to event was calculated from the date of enrolment to the date of first detection or progression in size of EV, or to the date of last EGDS, or death. The incidence rates of development of EV were described by the Kaplan-Meier plots, and compared using the logrank test. Data handling and analysis were performed with the Stata 10.0 ® package (Statacorp LP; College Station, TX, USA).
Results

Study population
Between January 2000 and March 2006, 145 patients with Child-Pugh A cirrhosis due to HCV were considered for anti-HCV therapy. Eight were excluded since they either had received previous endoscopic treatments for EV or were on primary or secondary prophylaxis with β-blockers. A total of 137 patients who fulfilled the inclusion criteria, were offered participation in the study; 10 (7%) patients, who refused to undergo endoscopic follow-up if an SVR was achieved, were excluded ( Figure 1) .
Among the 127 patients enrolled, 79 (62%) were males with a median age of 59 years. Overall, 53 (42%) patients were infected with HCV-1, 49 (38%) with HCV-2, 13 (10%) with HCV-3 and 12 (10%) with HCV-4. At enrolment, 110 (87%) patients did not show any EV, whereas 17 (13%) had F1 EV, in all cases 62 (49%) patients achieved an SVR, among whom were 17 (26%) HCV-1/4, 41 (82%) HCV-2 and 4 (31%) HCV-3 (Table 2 ) patients, with no significant differences across the treatment regimen groups (53% versus 52% versus 46%). Patients were followed up for a median period of 77 months (range 18-108) after treatment completion, with no differences between SVR and non-SVR patients (82 versus 75; P=0.4).
Portal hypertension-related events
Development or progression of EV occurred in 3/62 (5%) SVR patients versus 10/65 (15%) non-SVR patients (P=0.08), during a follow-up of 68 months (range 23-103) and 57 months (range 23-99), respectively (P=0.3).
De novo EV were detected in 2/57 SVR versus 8/53 non-SVR patients (3.5% versus 15%; P=0.047), with an 8-year cumulative probability of 6% and 30%, respectively (P=0.03; Figure 2 ), during a median period of 53 months (range 43-63) in SVR, and of 56 months (range 20-89) in non-SVR patients, after treatment completion. Two of the non-SVR patients developed both EV and RWM, with none of them bleeding from ruptured EV. Overall, the size of varices increased in 3 (18%) patients, including 1/5 with an SVR and 2/12 with a treatment failure (P=0.87), in all cases after the first post-treatment EGDS. None of the 17 patients with F1 EV at baseline had RWM. During the study period, two treatment failure patients and no SVR patients bled from ruptured EV. One of these patients died (Table 3) . By univariate analysis, treatment failure was the only predictor of de novo EV (Table 4) . Importantly, for all the patients in the study, including those who developed or worsened EV, alcohol use was excluded by patients' interviews and blood tests examinations. Moreover, in the only patient who developed both de novo EV and HCC, the latter was diagnosed 36 months after the EGDS that showed enlarged varices.
Other complications of cirrhosis
At variance with the follow-up for the assessment of variceal development or progression (68 and 57 months for SVR and non-SVR, respectively), the median follow-up for other complications of cirrhosis, including bleeding, was 79 months (range 24-112; SVR 85 and non-SVR 79), since it was calculated from the date of enrolment to the date of first complication development or death. Liver-related events were overall less frequent among the SVR than non-SVR patients (5% versus 17%; P=0.03). HCC was the most frequent complication, with an incidence of 0.5% per year among the SVR patients and 2.1% per year among non-SVR patients (P=0.21). Ascites developed in one patient, while no cases of jaundice or encephalopathy were observed (Table 5) . 
Survival
Overall, 9 patients died (4 SVR versus 5 non-SVR). Among non-SVR patients, three died of HCC progression, one of haematemesis and one of liver failure. In SVR patients, there was one case of liver-related death, due to HCC, only.
Discussion
This prospective study, aimed to assess whether a successful anti-HCV treatment could modify the course of portal hypertension in patients with compensated cirrhosis due to HCV, did demonstrate a reduction but not the abrogation of de novo EV in SVR patients. Importantly, in patients with established EV, the achievement of an SVR did not prevent the size progression of EV, thus making endoscopic surveillance still necessary in SVR patients too. Indeed, among the 110 EV-free patients treated with IFN who were followed-up for a median period of 60 months with regular EGDS, EV developed in 2/57 patients with an SVR, and in 8/53
patients not achieving an SVR (3.5% versus 15%; P=0.047), whereas EV progressed in size at similar rates among SVR and non-SVR patients with F1 EV at baseline (1/5 versus 2/12). Since the number of patients with variceal enlargement was quite small, despite a reasonable follow-up duration, our conclusions regarding variceal size progression despite SVR achievement is weak by definition. However, given the prospective nature of the study, a follow-up with regular clinical assessment, ultrasound and blood tests enabled us to confidently exclude the role of potential variables, other than SVR, able to influence variceal enlargement, such as alcohol consumption or portal vein thrombosis, thus confirming that, albeit in few cases, variceal progression can occur despite SVR achievement. Moreover, this is in agreement with our data concerning the de novo development of EV despite SVR achievement, which can occur, although at a lower extent, also in SVR patients. Our findings compare well with two recent studies, which were the first to demonstrate a beneficial effect of SVR on the course of portal hypertension, assessed in terms of porto-caval pressure gradient [29, 30] and with another more recent study demonstrating a reduction of de novo EV in SVR cirrhotics [28] . The latter study showed prevention of EV development in 34 patients with cirrhosis due to HCV who achieved an SVR, during a median observation period of 11.4 years, whereas 32% of untreated patients and 32% of patients with a treatment failure had EV detected at any time interval of endoscopic surveillance. Compared with these reports, however, our study provides some additional information, whereas the previous multicentre study permits higher external applicability of findings. The present single-centre study benefits from the consecutive enrolment of all patients undergoing IFN therapy, that effectively negates any selection bias, by the performance of all EGDS examinations by an expert team that resulted in a standardized definition of EV and lastly had a remarkable rate of compliance, since none of the patients enrolled were lost to follow-up or escaped the programmed investigations. The lack of selection bias is confirmed by the 1% and 2.4% yearly rates of clinical decompensation and HCC, respectively, observed in our set of patients, which compare well with previous studies in similar patients in Italy [6, 7] . Most importantly, since our study focused on patients treated with the more potent standard of care IFN/RBV combination, we were able to recruit more SVR patients compared to the previous study [28] based on the less efficacious IFN monotherapy (62 versus 34). This likely explains the slightly different rates of EV development in SVR patients that are reported in the two studies. The report by Bruno et al. [28] of no cases of EV in SVR patients might in fact reflect that the study was underpowered to assess this end point, thus failing to identify the small residual risk of EV development that we report in a larger population of responders. This difference, albeit small, has important clinical implications, since the residual risk of EV development following an SVR calls for continued endoscopic surveillance. Although we do acknowledge this endoscopic strategy might not be cost-effective, the application of a more relaxed time period between EGDS examinations might translate into a clinical and economic benefit for our patients and the medical health system. Our choice of also enrolling patients with small EV at baseline allowed us to evaluate whether an SVR could prevent the volumetric progression of EV too, a question that could not be addressed by the Italian multicentric study which did not enrol these patients. With all the caveats related to the small sample size, our study indicates that among the 17 patients with initially small EV, 3 had progression of EV including 1 who achieved an SVR (from F1 to F2), further supporting continued endoscopic surveillance in SVR cirrhotics. Despite these small but significant differences, both studies concur in demonstrating low risk of bleeding from ruptured EV in SVR patients confirming previous observations in cohort studies in Europe, North America and Japan that showed a significant reduction in the annual incidence rates of bleeding from ruptured EV following an SVR [22] [23] [24] . Nonetheless, we acknowledge that one major weakness of our study was the limited sample size and the lack of video recording of all EGDS exams to minimize the potential bias related to the inter-observer variability in EV classification.
In conclusion, our prospective study supports that patients with cirrhosis due to HCV who achieve an SVR still require continued endoscopic surveillance owing to the residual risk of de novo EV. EV-free patients might receive relaxed surveillance in view of the very low risk of EV, sparing the need for costly procedures whilst ameliorating the compliance of post-treatment follow-up.
